Read by QxMD icon Read

Journal of Thoracic Oncology

Stefano Occhipinti, Jeff Dunn, Dianne L O'Connell, Gail Garvey, Patricia C Valery, David Ball, Kwun M Fong, Shalini Vinod, Suzanne Chambers
OBJECTIVE: To examine the personal experiences of people with lung cancer and of their caregivers and how stigma manifests throughout the patient's social network. METHODS: Qualitative thematic analysis conducted on interviews with 28 lung cancer patients and caregivers. Telephone interviews were conducted and transcribed verbatim. Data analysis was guided by contemporary stigma theory. RESULTS: Patients and caregivers reported high levels of felt stigma and concomitant psychological distress in response to the diagnosis of lung cancer...
July 5, 2018: Journal of Thoracic Oncology
Jonathan W Riess, David R Gandara, Garrett M Frampton, Russell Madison, Nir Peled, Jose A Bufill, Grace Dy, Sai-Hong Ignatius Ou, Philip J Stephens, John McPherson, Primo N Lara, Rebekah A Burich, Jeffrey S Ross, Vincent A Miller, Siraj M Ali, Philip C Mack, Alexa B Schrock
INTRODUCTION: EGFR exon 20 insertions (EGFRex20ins) comprise an uncommon subset of EGFR activating alterations relatively insensitive to first and second-generation EGFR tyrosine kinase inhibitors (TKIs). However, recent early clinical data suggests these patients may benefit from newer generation EGFR-TKIs. Comprehensive genomic profiling (CGP) identifies a broad spectrum of EGFRex20ins and associated co-occurring genomic alterations (GA) present in non-small cell lung cancer (NSCLC) METHODS: Hybrid capture-based CGP was performed prospectively on 14,483 clinically annotated consecutive NSCLC specimens to a mean coverage depth of >650X for 236 or 315 cancer-related genes...
July 5, 2018: Journal of Thoracic Oncology
Timothy J Williamson, Alyssa K Choi, Julie C Kim, Edward B Garon, Jenessa R Shapiro, Michael R Irwin, Jonathan W Goldman, Krikor Bornyazan, James M Carroll, Annette L Stanton
INTRODUCTION: Internalized lung cancer stigma (i.e., feelings of regret, shame, and self-blame about one's lung cancer) is related to poorer psychological outcomes. Less is known about how internalized stigma relates to physical and functional outcomes or how constrained disclosure (i.e., avoidance of or discomfort about disclosing one's lung cancer status to others) relates to well-being. Furthermore, no study has examined whether internalized stigma and constrained disclosure predict changes in well-being for lung cancer patients...
July 5, 2018: Journal of Thoracic Oncology
Tejas Patil, Derek E Smith, Paul A Bunn, Dara L Aisner, Anh T Le, Mark Hancock, William T Purcell, Daniel W Bowles, D Ross Camidge, Robert C Doebele
INTRODUCTION: Central nervous system (CNS) metastases in lung cancer are a frequent cause of morbidity and mortality. There are conflicting data on the incidence of CNS metastases in stage IV ROS1+ non-small cell lung cancer (NSCLC) and rate of CNS progression on crizotinib. METHODS: A retrospective review of 579 patients with stage IV NSCLC between June 2008 to December 2017 was performed. Brain metastases and oncogene status (ROS1, ALK, EGFR, KRAS, BRAF, and other) were recorded...
July 5, 2018: Journal of Thoracic Oncology
Kartik Sehgal, Mary Linton B Peters, Paul A VanderLaan, Deepa Rangachari, Susumu S Kobayashi, Daniel B Costa
No abstract text is available yet for this article.
July 5, 2018: Journal of Thoracic Oncology
Emily Kinsey, Elizabeth Ajazi, Xiaofei Wang, Mary Ann Mayzie Johnston, Jeffrey Crawford
INTRODUCTION: Muscle wasting has detrimental effects including increased mortality. Identifying patients at risk can guide treatment efforts. METHODS: POWER 1 and 2 were randomized, double blind, placebo-controlled, multinational Phase III trials of 600 lung cancer patients initiating chemotherapy to assess the efficacy of enobosarm on prevention and treatment of muscle loss. We performed a secondary analysis restricted to the control group using a cumulative logit model for ordinal outcome to determine which baseline characteristics predicted physical and functional loss during chemotherapy...
July 4, 2018: Journal of Thoracic Oncology
Yanhong Liu, Christine M Lusk, Michael H Cho, Edwin K Silverman, Dandi Qiao, Ruyang Zhang, Michael E Scheurer, Farrah Kheradmand, David A Wheeler, Spiridon Tsavachidis, Georgina Armstrong, Dakai Zhu, Ignacio I Wistuba, Chi-Wan B Chow, Carmen Behrens, Claudio W Pikielny, Christine Neslund-Dudas, Susan M Pinney, Marshall Anderson, Elena Kupert, Joan Bailey-Wilson, Colette Gaba, Diptasri Mandal, Ming You, Mariza de Andrade, Ping Yang, John K Field, Triantafillos Liloglou, Michael Davies, Jolanta Lissowska, Beata Swiatkowska, David Zaridze, Anush Mukeriya, Vladimir Janout, Ivana Holcatova, Dana Mates, Sasa Milosavljevic, Ghislaine Scelo, Paul Brennan, James McKay, Geoffrey Liu, Rayjean J Hung, David C Christiani, Ann G Schwartz, Christopher I Amos, Margaret R Spitz
BACKGROUND: Genome-wide association studies (GWAS) are widely used to map genomic regions contributing to lung cancer (LC) susceptibility but they typically do not identify the precise disease-causing genes/variants. To unveil the inherited causal LC variants, we performed focused exome sequencing analyses on genes located in 121 GWAS loci previously implicated in the risk of LC, chronic obstructive pulmonary disease, pulmonary function level and smoking behavior. METHODS: Germline DNA from 260 LC cases and 318 controls were sequenced utilizing VCRome 2...
July 4, 2018: Journal of Thoracic Oncology
Yi-Long Wu, Shun Lu, You Lu, Jianying Zhou, Yuan-Kai Shi, Virote Sriuranpong, James C M Ho, Choo Khoon Ong, Chun-Ming Tsai, Chin-Hee Chung, Keith D Wilner, Yiyun Tang, Elizabeth T Masters, Paulina Selaru, Tony S Mok
INTRODUCTION: The phase III randomized PROFILE 1014 study demonstrated superiority of crizotinib to first-line chemotherapy in prolonging progression-free survival (PFS) in previously untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced nonsquamous non-small cell lung cancer (NSCLC). This result was consistent in the smaller subset of East Asian patients in PROFILE 1014. The subsequent study reported here prospectively evaluated crizotinib in a larger East Asian patient population...
June 29, 2018: Journal of Thoracic Oncology
Luciano Mutti, Tobias Peikert, Bruce W S Robinson, Arnaud Scherpereel, Anne S Tsao, Marc de Perrot, Gavitt A Woodard, David M Jablons, Jacinta Wiens, Fred R Hirsch, Haining Yang, Michele Carbone, Anish Thomas, Raffit Hassan
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that arises from the mesothelial surface of the pleural and peritoneal cavities, the pericardium, and rarely, the tunica vaginalis. The incidence of MPM is expected to increase worldwide in the next two decades. However, even with the use of multimodality treatment, MPM remains challenging to treat with a 5-year survival rate of less than 5%. The International Association for the Study of Lung Cancer has gathered experts in different areas of mesothelioma research and management to summarize the most significant scientific advances and new frontiers related to mesothelioma therapeutics...
June 29, 2018: Journal of Thoracic Oncology
Kevin Shiue, Alberto Cerra-Franco, Ronald Shapiro, Neil Estabrook, Edward M Mannina, Christopher R Deig, Sandra Althouse, Sheng Liu, Jun Wan, Yong Zang, Namita Agrawal, Pericles Ioannides, Yongmei Liu, Chen Zhang, Colleen DesRosiers, Greg Bartlett, Marvene Ewing, Mark P Langer, Gordon Watson, Richard Zellars, Feng-Ming Kong, Tim Lautenschlaeger
INTRODUCTION: It remains unclear if histology should be independently considered when choosing stereotactic ablative body radiotherapy (SABR) dose prescriptions for non-small cell lung cancer (NSCLC). METHODS: The study population included 508 patients with 561 lesions between 2000 and 2016, of which 442 patients with 482 lesions had complete dosimetric information. Eligible patients had histologically or clinically diagnosed early-stage NSCLC and were treated with 3 to 5 fractions...
June 26, 2018: Journal of Thoracic Oncology
Laurel M Schunselaar, Kim Monkhorst, Vincent van der Noort, Ruud Wijdeven, Dennis Peters, Wilbert Zwart, Jacques Neefjes, Paul Baas
OBJECTIVES: The prognosis for patients with mesothelioma is poor, which urges the need for the development of better treatment options. Antibody drug conjugates (ADCs) are gaining interest as a therapeutic strategy in mesothelioma. 5T4 is an oncofetal protein overexpressed in mesothelioma with low expression in normal tissue and therefore a good candidate for ADC treatment. Here, we evaluated and manipulated 5T4 as a suitable antigen for ADC targeted therapy in patients with mesothelioma...
June 26, 2018: Journal of Thoracic Oncology
Kurtis D Davies, Anh T Le, Jamie Sheren, Hala Nijmeh, Katherine Gowan, Kenneth L Jones, Marileila Varella-Garcia, Dara L Aisner, Robert C Doebele
INTRODUCTION: ROS1 gene fusions are a well-characterized class of oncogenic driver found in approximately 1-2% of non-small cell lung cancer patients. ROS1-directed therapy in these patients is more efficacious and is associated with fewer side effects compared to chemotherapy and is thus now considered standard-of-care for patients with advanced disease. Consequently, accurate detection of ROS1 rearrangements/fusions in clinical tumor samples is vital. In this study, we compared the performance of three common molecular testing approaches on a cohort of ROS1 rearrangement/fusion-positive patient samples...
June 20, 2018: Journal of Thoracic Oncology
Susan Combs Scott, Nathan A Pennell
BACKGROUND: Checkpoint inhibitors augment the immune system's natural surveillance mechanisms and have increasing applications in non-small cell lung cancer (NSCLC). Immunosuppressive corticosteroids are also frequently used in this population to treat unwanted inflammation. Based on this mechanistic opposition, we investigated the interaction between nivolumab and corticosteroids in patients with advanced NSCLC. METHODS: A retrospective chart review of 210 NSCLC patients treated with nivolumab at the Cleveland Clinic was performed...
June 20, 2018: Journal of Thoracic Oncology
Jessica J Lin, Viola W Zhu, Adam J Schoenfeld, Beow Y Yeap, Ashish Saxena, Lorin A Ferris, Ibiayi Dagogo-Jack, Anna F Farago, Angela Taber, Anne Traynor, Smitha Menon, Justin F Gainor, Jochen K Lennerz, Andrew J Plodkowski, Subba R Digumarthy, Sai-Hong Ignatius Ou, Alice T Shaw, Gregory J Riely
BACKGROUND: The second-generation ALK inhibitor alectinib recently demonstrated superior efficacy compared to the first-generation ALK inhibitor crizotinib in advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC), establishing alectinib as the new standard first-line therapy. Brigatinib, another second-generation ALK inhibitor, has demonstrated substantial activity in patients with crizotinib-refractory ALK-positive NSCLC; however, its activity in the alectinib-refractory setting is unknown...
June 20, 2018: Journal of Thoracic Oncology
Janani S Reisenauer, Wadad Mneimneh, Sarah Jenkins, Aaron S Mansfield, Marie Christine Aubry, Karen J Fritchie, Mark S Allen, Shanda H Blackmon, Stephen D Cassivi, Francis C Nichols, Dennis A Wigle, K Robert Shen, Jennifer M Boland
INTRODUCTION: Solitary fibrous tumors (SFT) are rare mesenchymal neoplasms. Most follow a benign course, but a subset will recur or metastasize. Various risk stratification schemes have been proposed for SFT, but none have been universally endorsed and few have focused on pleuropulmonary SFT. METHODS: Histologic sections were examined from surgically resected pleuropulmonary SFT, with confirmatory immunohistochemistry. Patients were risk stratified using 4 prediction models as proposed by de Perrot, Demicco (original and modified), and Tapias...
June 20, 2018: Journal of Thoracic Oncology
Kenichi Suda, Jihye Kim, Isao Murakami, Leslie Rozeboom, Masaki Shimoji, Shigeki Shimizu, Christopher J Rivard, Tetsuya Mitsudomi, Aik-Choon Tan, Fred R Hirsch
INTRODUCTION: Data regarding the pre-treatment inter-tumor heterogeneity of potential biomarkers in advanced-stage lung cancers is limited. A finding of such heterogeneity between primary and metastatic lesions would prove valuable to determine if a metastatic lesion can be a surrogate for the primary tumor, as more biomarkers will likely be used in the future to inform treatment decisions. METHODS: We performed RNA sequencing to analyze inter-tumor heterogeneity in thirty specimens (primary tumors, intra-thoracic, and extra-thoracic metastatic lesions) obtained from five treatment-naïve lung cancer patients...
June 19, 2018: Journal of Thoracic Oncology
Josine Quispel-Janssen, Vincent van der Noort, Jeltje F de Vries, Marion Zimmerman, Ferry Lalezari, Erik Thunnissen, Kim Monkhorst, Robert Schouten, Laurel Schunselaar, Maria Disselhorst, Houke Klomp, Koen Hartemink, Sjaak Burgers, Wieneke Buikhuisen, Paul Baas
BACKGROUND: Malignant Pleural Mesothelioma (MPM) has limited treatment options and a poor outcome. PD-1/PD-L1 checkpoint inhibitors have proven efficacious in several cancer types. Nivolumab is a fully humanized monoclonal antibody against PD-1 with a favorable toxicity profile. In MPM, the immune system is considered to play an important role. We therefore tested nivolumab in recurrent MPM. METHODS: In this single center trial, patients with MPM received nivolumab 3mg/kg i...
June 13, 2018: Journal of Thoracic Oncology
Shidan Wang, Lin Yang, Bo Ci, Matthew Maclean, David E Gerber, Guanghua Xiao, Yang Xie
BACKGROUND: Small-cell lung cancer (SCLC) accounts for almost 15% of lung cancer cases in the United States. Nomogram prognostic models could greatly facilitate risk stratification and treatment planning, as well as more refined enrollment criteria for clinical trials. We developed and validated a new nomogram prognostic model for SCLC patients using a large SCLC patient cohort from the National Cancer Database (NCDB). METHODS: Clinical data of 24,680 SCLC patients diagnosed from 2004 to 2011 were used to develop the nomogram prognostic model...
June 11, 2018: Journal of Thoracic Oncology
Naoki Haratake, Tetsuzo Tagawa, Fumihiko Hirai, Gouji Toyokawa, Reiko Miyazaki, Yoshihiko Maehara
No abstract text is available yet for this article.
June 6, 2018: Journal of Thoracic Oncology
Carissa C Jones, Sarah Fletcher Mercaldo, Jeffrey D Blume, Angela S Wenzlaff, Ann G Schwartz, Heidi Chen, Stephen A Deppen, William S Bush, Dana C Crawford, Stephen J Chanock, William J Blot, Eric L Grogan, Melinda C Aldrich
INTRODUCTION: Lung cancer is a leading cause of cancer-related death worldwide. Racial disparities in LC survival exist between blacks and whites, yet are limited by categorical definitions of race. We sought to examine the impact of African ancestry on overall survival among black and white non-small cell lung cancer (NSCLC) cases. METHODS: Black and white incident NSCLC cases from the prospective Southern Community Cohort Study (N=425) were identified via linkage with state cancer registries in 12 Southern states...
June 6, 2018: Journal of Thoracic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"